Genie Fertility is a UK-based biotech startup developing non-invasive fertility diagnostics for uterine health using menstrual blood analysis. Powered by an ML multi-omics discovery platform built on data from over 200,000 fertility patients, it identifies novel biomarkers in the uterus lining to address up to 25% of fertility issues previously assessed only through invasive biopsies. The company works with leading IVF groups in the UK and Europe, backed by medical advisors from Imperial College London and Harvard Medical School, and plans diagnostics and therapeutics for reproductive conditions like PCOS and endometriosis.[1][3][7][8]
